Latest News

Special Authority Criteria Amendment for DMTs

May 26, 2021 | Advocacy

Multiple Sclerosis NZ received several reports from concerned patients regarding the ambiguity of the Special Authority Criteria for DMTs. With the support of Dr John Mottershead, Pharmac were approached for clarification. Concern centred around whether bilateral aids qualify for use […]


MS Treatments

August 18, 2017

The below disease modifying treatments (DMT’s) are available for the treatment of MS in New Zealand.   First line treatments for Relapsing Remitting MS (funded) Ocrevus® (Ocrelizumab) Gilenya® (Fingolimod) Aubagio® (teriflunomide) Tecfidera® (Dimethyl fumarate) Tysabri® (Natalizumab)   Second line treatments for […]


Tysabri®(Natalizumab)

August 18, 2017


Tecfidera® (Dimethyl fumarate)

August 18, 2017


Steroids

August 18, 2017